Fulgent Genetics, Inc.
For the period ended Mar 31, 2026. Filed May 1, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 1, 2026
FLGT$25.78-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flow from operating activities: | ||
| Net loss from consolidated operations | $(25,274) | $(11,899) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Equity-based compensation | 9,890 | 10,550 |
| Depreciation and amortization | 6,000 | 5,919 |
| Adjustment for credit losses | 1,189 | 2,075 |
| Noncash lease expense | 352 | 350 |
| Gain on disposal of fixed asset | (9) | (2) |
| Amortization of premium of marketable securities | (890) | (1,658) |
| Deferred taxes | (1,120) | (133) |
| Unrecognized tax benefits | 199 | 137 |
| Other | 1 | 21 |
| Changes in operating assets and liabilities: | ||
| Trade accounts receivable | 16,431 | (4,524) |
| Income tax | (1,394) | 1,761 |
| Other current and long-term assets | 2,791 | 804 |
| Accounts payable | (408) | (658) |
| Contract liabilities | (627) | 582 |
| Customer deposits | 2,470 | 83 |
| Accrued liabilities and other liabilities | (2,123) | (7,485) |
| Operating lease liabilities | (381) | (354) |
| Net cash provided by (used in) operating activities | 7,097 | (4,431) |
| Cash flow from investing activities: | ||
| Maturities of marketable securities | 81,711 | 32,445 |
| Proceeds from sale of fixed assets | 8 | 2 |
| Purchase of marketable securities | (10,011) | — |
| Purchases of fixed assets | (5,202) | (4,718) |
| Acquisition of businesses, net of cash | (55,567) | — |
| Net cash provided by investing activities | 10,939 | 27,729 |
| Cash flow from financing activities: | ||
| Repurchase of common stock | (40,078) | (8,679) |
| Common stock withholding for employee tax obligations | (4,200) | (1,887) |
| Repayment of notes payable | (476) | (470) |
| Principal paid for finance lease | (88) | (136) |
| Proceeds from exercise of stock options | 9 | — |
| Net cash used in financing activities | (44,833) | (11,172) |
| Effect of exchange rate changes on cash and cash equivalents | 3 | 11 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (26,794) | 12,137 |
| Cash, cash equivalents, and restricted cash at beginning of period | 50,328 | 55,279 |
| Cash, cash equivalents, and restricted cash at end of period | $23,534 | $67,416 |
| Supplemental disclosures of cash flow information: | ||
| Income taxes paid, net of refunds received | $(551) | $(1,633) |
| Interest paid | $44 | $61 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Purchases of fixed assets in accounts payable | $2,606 | $2,322 |
| Acquisition of business in accrued liabilities | $141 | $— |
| Operating lease right-of-use assets obtained in exchange for lease liabilities | $210 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.